The Rachel Maddow Show, 1/22/2021 Guests: Anthony Fauci
Jan 25, 2021 3:36:20 GMT
icemandios likes this
Post by c2crusher on Jan 25, 2021 3:36:20 GMT
The Rachel Maddow Show, 1/22/2021
Guests: Anthony Fauci, David Laufman
www.msnbc.com/rachel-maddow-show/transcript-rachel-maddow-show-1-22-2021-n1255475
MADDOW: And that`s the sort of theory of the case for the best shot for therapeutics. But is there anything that looks promising along those lines already? Or is this something that`s years away in terms of development?
FAUCI: No. Well, you know, normally under business as usual-type things, it might have been years away. But there are a number of companies that have candidates that they`re looking at, that might look pretty, you know, the companies are a little shy telling you about things, but being at the NIH where we fund scientists who are doing this, I think it`s going to be much sooner than we think.
That once you get something that looks like it`s a hit, as we call it, namely, something that really does act. You get it into a phase one trial quickly and because the situation is so dire in the sense of the need for therapeutics, you move it along. You don`t just want to forget about safety. Safety is always important. But if you can show it`s safe, has good antiviral activity, we can move relatively quickly on that.
And as I mentioned, there are a couple of candidates that are looking promising in the test tube, and then from there you go to an animal model and then get it into humans.
Guests: Anthony Fauci, David Laufman
www.msnbc.com/rachel-maddow-show/transcript-rachel-maddow-show-1-22-2021-n1255475
MADDOW: And that`s the sort of theory of the case for the best shot for therapeutics. But is there anything that looks promising along those lines already? Or is this something that`s years away in terms of development?
FAUCI: No. Well, you know, normally under business as usual-type things, it might have been years away. But there are a number of companies that have candidates that they`re looking at, that might look pretty, you know, the companies are a little shy telling you about things, but being at the NIH where we fund scientists who are doing this, I think it`s going to be much sooner than we think.
That once you get something that looks like it`s a hit, as we call it, namely, something that really does act. You get it into a phase one trial quickly and because the situation is so dire in the sense of the need for therapeutics, you move it along. You don`t just want to forget about safety. Safety is always important. But if you can show it`s safe, has good antiviral activity, we can move relatively quickly on that.
And as I mentioned, there are a couple of candidates that are looking promising in the test tube, and then from there you go to an animal model and then get it into humans.